|
|
|
|
|
|
|
|
|
|
|
|
|
Bringing PREMs and PROMs Into Value-Based Care
Healthcare Innovation, September 18, 2024 |
|
|
|
Study: Prescribing continuous glucose monitors may improve outcomes
Fierce Healthcare, September 18, 2024 |
|
|
|
A program that cuts antibiotic use by 50% without hurting
patient satisfaction
Becker's Hospital Review, September 17, 2024 |
|
|
|
Biden administration unveils multi-agency patient safety
programs
Fierce Healthcare, September 17, 2024 |
|
|
|
1 in 3 hospital medication errors are IT-related: Study
Becker's Hospital Review, September 16, 2024 |
|
|
|
Four strategies to advance value-based care
Medical Economics, September 12, 2024 |
|
|
|
Nationwide hospital mortality risk fell as acuity, volumes rose, report
finds
Fierce Healthcare, September 12, 2024 |
|
|
|
Scaling VBC: Addressing Systemic Issues With Payer-Provider Collaboration
The American Journal of Managed Care, September 10, 2024 |
|
|
|
New guidelines reduce pediatric mortality by 74%: Study
Becker's Hospital Review, September 4, 2024 |
|
|
|
How specialty practices can succeed in MIPS and value-based care
Physicians Practice, September 3, 2024 |
|
|
|
|
|
JAMA Network Open: Care Quality for MA versus TM
Enrollees Receiving Chemotherapy
1. MA enrollees had less chemotherapy-related Emergency
Department use than TM beneficiaries: 20.9% in MA vs 23.4% in
TM.
2. MA enrollees had fewer chemotherapy-related hospitalizations:
12.8% in MA vs 13.6% in TM
3. MA beneficiaries had higher avoidable Emergency Department
use than TM beneficiaries: 11.0% in MA vs 10.5% in TM
4. MA and TM had similar rates of preventable hospitalizations:
4.5% for each
5. There was no difference in survival during 18 months after
chemotherapy initiation: 525 days in both MA and TM
Notes: MA: Medicare Advantage; TM: traditional
Medicare. Results from a study of cohort study of 96,501 MA and
206,274 TM beneficiaries receiving chemotherapy. Mean outcomes
were measured during the 6-month period following the first
chemotherapy treatment, or until death if it occurred earlier.
Source:
"Resource Use and Care Quality Differences Among Medicare
Beneficiaries Undergoing Chemotherapy," JAMA Network Open,
September 20, 2024. |
|
|
check out more lists on
healthsprocket. "What's on your list?" |
|
|
|
|
|
|
|
|
Closing Gaps in Health and Health Care
While healthcare spending has increased, gaps in healthcare
outcomes and access have widened. What steps are being taken to
ensure that scientific advances and innovations are translating
to improvements in health and well-being? Leaders in this
session speak about the opportunities ahead to close the gaps in
health and health care and lead to better health for more
people.
|
|
|
|
|
|
|
|
|
Increased Time & Decreasing Reimbursements: Has
VBC Contributed to Burnout?
The Journal of Arthroplasty, September 20, 2024 |
|
Social Determinants of Health and Insurance Claim Denials
for Preventive Care
JAMA Network Open, September 18, 2024 |
|
Using Patient Experience Surveys to Identify Potential
Safety Breakdowns
Journal of Patient Safety, September 17, 2024 |
|
Outcomes by Race and Ethnicity Following a Medicare Bundled
Payment Program
JAMA Network Open, September 17, 2024 |
|
Community Oncology Alliance Releases Quality & Value
Standards in Cancer Care
Implementation Science, August 5, 2024 |
|
Childhood Opportunity Index and Low-Value Care in
Children’s Hospitals
Pediatrics, September 9, 2024 |
|
Readmissions in Sepsis Survivors: Discharge Setting Risks
The American Journal of Critical Care, September 1, 2024 |
|
Reducing Handoff Communication Failures and Inequities in
Healthcare
The Joint Commission, August 22, 2024 |
|
|
|
|
|
HealthExecWeek
provides a weekly wealth of business intelligence and insights covering
the spectrum of subjects filling the healthcare business arena. Because
doing business in the world of healthcare today isn’t siloed, neither
is our coverage. You will be able to stay a step ahead in a healthcare
business environment where all subject matter lines seem to blur and
cross over to the next.
|
|
|
|
|
|
|
|
|
|
|
|
|
|